Zobrazeno 1 - 10
of 67
pro vyhledávání: '"Peter A. W. te Boekhorst"'
Autor:
Rinse Ubbink, Lucia W. J. M. Streng, Nicolaas J. H. Raat, Floor A. Harms, Peter A. W. te Boekhorst, Robert J. Stolker, Egbert G. Mik
Publikováno v:
Biomedicines, Vol 11, Iss 7, p 1873 (2023)
In light of the associated risks, the question has been raised whether the decision to give a blood transfusion should solely be based on the hemoglobin level. As mitochondria are the final destination of oxygen transport, mitochondrial parameters ar
Externí odkaz:
https://doaj.org/article/5a42e3e2173b4609b07f568528588d43
Publikováno v:
HemaSphere, Vol 5, Iss 7, p e595 (2021)
Externí odkaz:
https://doaj.org/article/63b2ba10b3264ce284e909f6d531b134
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
Current treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors (TKI) is effective in many patients, but is not curative and frequently limited by intolerance or resistance. Also, treatment free remission is a novel option for CML
Externí odkaz:
https://doaj.org/article/59280be051e0463c9d2df3eea2f43316
Autor:
Alessandro M. Vannucchi, Peter A. W. te Boekhorst, Claire N. Harrison, Guangsheng He, Marianna Caramella, Dietger Niederwieser, Françoise Boyer-Perrard, Minghui Duan, Nathalie Francillard, Betty Molloy, Monika Wroclawska, Heinz Gisslinger
Publikováno v:
Haematologica, Vol 104, Iss 5 (2019)
EEXPAND (phase Ib, dose-finding study) evaluated the starting dose of ruxolitinib in patients with myelofibrosis with baseline platelet counts of 50-99×109/L. The study consisted of dose-escalation and safety-expansion phases. Based on the baseline
Externí odkaz:
https://doaj.org/article/dcdd30fc08a34d069d9bc9af3fd3e65b
Autor:
Madelon van Agteren, Willem Weimar, Annelies E. de Weerd, Peter A. W. te Boekhorst, Jan N. M. Ijzermans, Jaqueline van de Wetering, Michiel G. H. Betjes
Publikováno v:
Journal of Transplantation, Vol 2014 (2014)
This study describes the single center experience and long-term results of ABOi kidney transplantation using a pretransplantation protocol involving immunoadsorption combined with rituximab, intravenous immunoglobulins, and triple immune suppression.
Externí odkaz:
https://doaj.org/article/2a9358ad322442dd9ac78b7c53c93225
Autor:
Mar Bellido, Peter A. W. te Boekhorst
Publikováno v:
Advances in Hematology, Vol 2012 (2012)
JAK2 is a tyrosine kinase gene that plays an essential role in the development of normal haematopoiesis. Hyperactivation of JAK2 occurs in myeloproliferative neoplasms by different mechanisms. As a consequence, JAK2 inhibitors have been designed to s
Externí odkaz:
https://doaj.org/article/f3891921da364fcf90182c5640924357
Autor:
Mik, Rinse Ubbink, Lucia W. J. M. Streng, Nicolaas J. H. Raat, Floor A. Harms, Peter A. W. te Boekhorst, Robert J. Stolker, Egbert G.
Publikováno v:
Biomedicines; Volume 11; Issue 7; Pages: 1873
In light of the associated risks, the question has been raised whether the decision to give a blood transfusion should solely be based on the hemoglobin level. As mitochondria are the final destination of oxygen transport, mitochondrial parameters ar
Publikováno v:
Leukemia, 36(1), 275-278. Nature Publishing Group
Autor:
Stefan Sleijfer, John W.M. Martens, Harmen J.G. van de Werken, Corine M. Beaufort, Anieta M. Sieuwerts, Job van Riet, Nikolas H. Stoecklein, Jaco Kraan, Yorick Sandberg, Peter A. W. te Boekhorst, Martijn P. Lolkema, Wytske M. van Weerden, Anouk C. de Jong, Paul Hamberg, S. Erkens-Schulze, Lisanne F. van Dessel, L. Mout, Thomas L.C. Woo, Ronald de Wit, Rui P L Neves
Publikováno v:
European Journal of Cancer, 150, 179-189. Elsevier Ltd.
Background: Circulating tumour cell (CTC)–derived organoids have the potential to provide a powerful tool for personalised cancer therapy but are restrained by low CTC numbers provided by blood samples. Here, we used diagnostic leukapheresis (DLA)
Autor:
Sonja Zweegman, Shanti Natarajan-Amé, Francesco Passamonti, Raajit K. Rampal, Moshe Talpaz, Daobin Zhou, Kelly McCaul, Mary Frances McMullin, Candido E. Rivera, Hiroshi Kawabata, Günther Gastl, H. Joachim Deeg, Heinz Gisslinger, Angela Hamblin, Vincent Ribrag, Reinier Raymakers, John Catalano, P. Mineur, Fabrizio Pane, Giuseppe Saglio, Jean Loup Demory, Josef T. Prchal, Qian Jiang, Kudrat Abdulkadyrov, Emmanuel C. Besa, Richard F. Schlenk, Gary J. Schiller, John T. Reilly, Adam J. Mead, Robert Peter Gale, William Stevenson, Gemma Buck, Kazuma Ohyashiki, Dominique Bordessoule, Mark Drummond, Jianyong Li, Ayalew Tefferi, Ting Liu, Tomoko Hata, Jianhua Zhong, Juan Carlos Hernandez Boluda, Damiano Rondelli, Norio Komatsu, John Mascarenhas, Zhixiang Shen, Timothy Devos, Alessandro M. Vannucchi, Katsuto Takenaka, Randall Brown, Haifa K. Al-Ali, Thomas J. Nevill, Jen Chin Wang, Daniel Tesfa, Jennifer O'Sullivan, Andrew Turner, Guanlin Wang, Galina Salogub, Claire N. Harrison, Dragana Milojkovic, Giovanni Barosi, James W. Vardiman, Peter A. W. te Boekhorst, Ruben A. Mesa, Jan Van Droogenbroeck, Manana Sokolova, Vikas Gupta, Lennart Nilsson, Andrey Zaritskiy, Nikolaos Barkas, Werner Linkesch, Mario Cazzola, Jean-Jacques Kiladjian, Ramon V. Tiu, Kiyoshi Ando, Onima Chowdhury, Emilio Ojeda, Martin Griesshammer, Christian Recher, Alessandro Rambaldi, Francisco Cervantes, Giorgina Specchia
Publikováno v:
Leukemia
for the RESUME trialists 2020, ' Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide ', Leukemia . https://doi.org/10.1038/s41375-020-0979-6, https://doi.org/10.1038/s41375-020-0979-6
Chowdhury, O, O’Sullivan, J, Barkas, N, Wang, G, Buck, G, Hamblin, A, Tefferi, A, Al-Ali, H K, Barosi, G, Devos, T, Gisslinger, H, Jiang, Q, Kiladjian, J J, Mesa, R, Passamonti, F, Ribrag, V, Schiller, G, Vannucchi, A M, Zhou, D, McMullin, M F, Zhong, J, Gale, R P, Mead, A J, Catalano, J, Stevenson, W, Gastl, G, Linkesch, W, Van Droogenbroeck, J, Mineur, P, Gupta, V, Turner, A, Nevill, T, Li, J, Shen, Z, Liu, T, Bordessoule, D, Natarajan-Amé, S, Recher, C, Demory, J L, Schlenk, R, Griesshammer, M, Cazzola, M, Saglio, G, Specchia, G, Rambaldi, A, Pane, F, Zweegman, S, te Boekhorst, P, Raymakers, R, Abdulkadyrov, K, Sokolova, M, Salogub, G, Zaritskiy, A, Cervantes, F, Boluda, J C H, Ojeda, E, Tesfa, D, Nilsson, L, Drummond, M, Reilly, J, Harrison, C, Milojkovic, D, Rivera, C, Besa, E, Deeg, H J, Mascarenhas, J, Prchal, J, Tiu, R, Talpaz, M, Wang, J C, Rampal, R, Rondelli, D, McCaul, K, Brown, R, Komatsu, N, Ohyashiki, K, Ando, K, Kawabata, H, Takenaka, K, Hata, T, Vardiman, J & for the RESUME trialists 2021, ' Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide ', Leukemia, vol. 35, no. 4, pp. 1197-1202 . https://doi.org/10.1038/s41375-020-0979-6
Leukemia, 35(4), 1197-1202. Nature Publishing Group
for the RESUME trialists 2020, ' Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide ', Leukemia . https://doi.org/10.1038/s41375-020-0979-6, https://doi.org/10.1038/s41375-020-0979-6
Chowdhury, O, O’Sullivan, J, Barkas, N, Wang, G, Buck, G, Hamblin, A, Tefferi, A, Al-Ali, H K, Barosi, G, Devos, T, Gisslinger, H, Jiang, Q, Kiladjian, J J, Mesa, R, Passamonti, F, Ribrag, V, Schiller, G, Vannucchi, A M, Zhou, D, McMullin, M F, Zhong, J, Gale, R P, Mead, A J, Catalano, J, Stevenson, W, Gastl, G, Linkesch, W, Van Droogenbroeck, J, Mineur, P, Gupta, V, Turner, A, Nevill, T, Li, J, Shen, Z, Liu, T, Bordessoule, D, Natarajan-Amé, S, Recher, C, Demory, J L, Schlenk, R, Griesshammer, M, Cazzola, M, Saglio, G, Specchia, G, Rambaldi, A, Pane, F, Zweegman, S, te Boekhorst, P, Raymakers, R, Abdulkadyrov, K, Sokolova, M, Salogub, G, Zaritskiy, A, Cervantes, F, Boluda, J C H, Ojeda, E, Tesfa, D, Nilsson, L, Drummond, M, Reilly, J, Harrison, C, Milojkovic, D, Rivera, C, Besa, E, Deeg, H J, Mascarenhas, J, Prchal, J, Tiu, R, Talpaz, M, Wang, J C, Rampal, R, Rondelli, D, McCaul, K, Brown, R, Komatsu, N, Ohyashiki, K, Ando, K, Kawabata, H, Takenaka, K, Hata, T, Vardiman, J & for the RESUME trialists 2021, ' Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide ', Leukemia, vol. 35, no. 4, pp. 1197-1202 . https://doi.org/10.1038/s41375-020-0979-6
Leukemia, 35(4), 1197-1202. Nature Publishing Group